Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia

Keyphrases

• Acute Effects 25%
• Acute Lymphoblastic Leukemia 100%
• Alkylating Agents 25%
• Anthracyline 25%
• B Cells 25%
• B-cell Acute Lymphoblastic Leukemia (B-ALL) 50%
• B-cell Leukemia 25%
• B-precursor 25%
• Cell Aging 25%
• Cell Count 25%
• Cell-to-cell 25%
• Central Nervous System 25%
• Child or Adolescent 25%
• Children Exposure 25%
• Continuation Therapy 25%
• Cytarabine 75%
• Event-free Survival 25%
• Hydrocortisone 25%
• Immunophenotypic Profile 25%
• Immunophenotyping 100%
• Induction Therapy 25%
• Infant Acute Lymphoblastic Leukemia 25%
• Infant Leukemia 25%
• Intravesical Chemotherapy 25%
• Irradiation 25%
• L-asparaginase 50%
• Late Effects 25%
• Leukocyte Count 50%
• Leukocytes 100%
• Mercaptopurine 25%
• Methotrexate 50%
• Moderate Dose 100%
• Multi-agent 25%
• Newly Diagnosed 25%
• Pediatric Oncology 25%
• Pre-B Cells 25%
• Precursor B-cell Acute Lymphoblastic Leukemia 25%
• Precursor Cells 25%
• Prednisone 50%
• Preventive Treatment 25%
• Progenitor Cells 25%
• T Cells 75%
• T-cell Acute Lymphoblastic Leukemia (T-ALL) 25%
• Therapy Protocols 25%
• Therapy Regimen 25%
• Treatment Protocol 25%

Immunology and Microbiology

• B Cell 66%
• Cell Aging 16%
• Cell Count 16%
• Central Nervous System 16%
• Event Free Survival 16%
• Leukocyte 100%
• Leukocyte Count 33%
• Methotrexate 100%
• Precursor 33%
• Prednisone 33%
• Pulse Rate 16%
• T Cell 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Lymphoblastic Leukemia 100%
• Alkylating Agent 11%
• Asparaginase 22%
• Chemotherapy 11%
• Childhood Cancer 11%
• Cytarabine 33%
• Event Free Survival 11%
• Hydrocortisone 11%
• Intrathecal 11%
• Leukemia 11%
• Mercaptopurine 11%
• Methotrexate 66%
• Prednisone 22%
• Vincristine 22%